Latest News & Features
Refine Search
Americas
Eduardo Andretto was selected in the LSIPR 50 2017 publication for his influence on the life sciences industry. He featured in the legal section, as LSIPR reports. 10 November 2017
Americas
Judy Jarecki Black was selected in the LSIPR 50 2017 publication for her influence on the life sciences industry. She featured in the legal section, as LSIPR reports. 10 November 2017
Big Pharma
Jörg Thomaier was selected in the LSIPR 50 2017 publication for his influence on the life sciences industry. He featured in the legal section, as LSIPR reports. 10 November 2017
Americas
Mike Young was selected in the LSIPR 50 2017 publication for his influence on the life sciences industry. He featured in the legal section, as LSIPR reports. 10 November 2017
Americas
Raj Panjabi was selected in the LSIPR 50 2017 publication for his influence on the life sciences industry. He featured in the business and innovation section, as LSIPR reports. 9 November 2017
Biotechnology
In September 2016, the German Federal Supreme Court decided a patent case that could have a major impact on companies working in the diagnostics field. Joachim Wachenfeld of Vossius & Partner reports. 9 November 2017
Americas
Past successes by trailblazers in other biotechnological fields could assist potential patentees navigate legal bumps along the road to IP protection for CRISPR-related inventions, as Patricia Carson and Ashley Ross of Kirkland & Ellis describe. 9 November 2017
Americas
Fake pharmaceuticals not only harm innovators, they can have tragic consequences, and require a robust response from the authorities. LSIPR assesses how officials, particularly in South America, are responding to the threat. 1 November 2017
Asia
Based in Singapore, biotech company Aslan Pharmaceuticals specialises in developing new treatments to fight cancers that are prevalent in Asia, often requiring licensing deals to ensure it is fully equipped. LSIPR spoke to general counsel Ben Goodger to find out more. 1 November 2017
Americas
With the PTAB facing questions over its authority and even constitutionality, life sciences companies seem to be faring well, at least compared to other industries, as LSIPR finds out. 1 November 2017